- Exchange: OTC BB
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Ligand Pharmaceuticals Inc
+ Add to WatchlistLGNYZ:US
0.0150 USD 0.00000.00%As of 20:10:00 ET on 05/13/2013.
Snapshot for Ligand Pharmaceuticals Inc (LGNYZ)
| Open: | - | Day's Range: | - | Volume: | 618 |
|---|---|---|---|---|---|
| Previous Close: | 0.0150 | 52wk Range: | 0.0001 - 0.0200 | 1-Yr Rtn: | - |
Key Statistics for LGNYZ
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(-) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (ttm) | - |
| Est. EPS | - |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 0.00 |
| Shares Outstanding (M) | 0.00 |
| 30 Day Average Volume | 1,470 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | 1.22% |
| Cash Dividend (USD) | 0.0002 |
| Last Dividend | 01/16/2013 |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/08/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for LGNYZ
Company Profile & Key Executives for LGNYZ
Ligand Pharmaceuticals Incorporated develops drugs which regulate hormone activated intracellular receptors. These receptors play a role in regulating the genetic processes affecting diseases such as gynecological disorders, certain cancers, as well as cardiovascular, inflammatory, and skin diseases.
| John L HigginsPresident/CEO | Mathew W Foehr "Matt"Exec VP/COO |
| John P SharpVP:Finance/CFO | Charles S BerkmanVP/Secretary/General Counsel |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
LGNYZ News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page